Back to Search Start Over

Case report of a novel alpha1-antitrypsin null variant in Türkiye: Q0RİZE.

Authors :
Karadoğan, Dilek
Şahin, Ünal
Dreger, Bettina
Grandoso, Laura
Osaba, Lourdes
Source :
BMC Pulmonary Medicine; 2/21/2024, Vol. 24 Issue 1, p1-8, 8p
Publication Year :
2024

Abstract

Background: Alpha1-antitrypsin (AAT) is a serine protease inhibitor that serves as a counterbalance to the activity of elastases, e.g., neutrophil elastase in lung tissue. AAT deficiency (AATD) is a rare disorder usually arising from mutations to the SERPINA1 gene that codes for AAT. The most common AATD alleles are S and Z which produce ~ 40% and ~ 90% reductions in serum AAT, respectively. Rare genetic variants (> 500 identified) can also be associated with mild to severe AATD. Results: This report describes a novel mutation of SERPINA1 producing AATD, which we have designated, Q0<subscript>RİZE</subscript>. This mutation was identified in a 44-year-old woman admitted with massive hemoptysis and treated with bronchial artery embolization. Computed tomography revealed centriacinar and panacinar emphysema with prominent air entrapment, atelectasis, and localized bronchiectasis. Serum AAT was < 0.27 g/L (below detection limit). Genetic analysis showed homozygous deletion of exons I to III. Conclusions: Although many SERPINA1 variants have been identified, variants with large deletions and identified in a homozygous individual, as seen in this case with Q0<subscript>RIZE,</subscript> are uncommon. AATD is an underdiagnosed and undertreated disease. Wider screening of COPD patients could result in earlier diagnosis and treatment that could preserve lung function. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
14712466
Volume :
24
Issue :
1
Database :
Complementary Index
Journal :
BMC Pulmonary Medicine
Publication Type :
Academic Journal
Accession number :
175566908
Full Text :
https://doi.org/10.1186/s12890-024-02900-6